Alzheimer's disease (AD) is an age-related neurodegenerative disease characterized 
modification that reflects glucose metabolism is disrupted in the brains of patients with AD (Alfaro et al., 2012; Forster et al., 2014; Wang et al., 2017; Zhu, Shan, Yuzwa, & Vocadlo, 2014) . The OGlcNAc modification, regulated by O-GlcNAc transferase (OGT, an enzyme that adds O-GlcNAc to proteins from Uridine diphosphate N-acetylglucosamine (UDP-GlcNAc)) and O-GlcNAcase (OGA, and enzyme that removes O-GlcNAc from proteins), is a dynamic process, affected in various human diseases as well as many biological processes (Bond & Hanover, 2015; . A recent studies on proteomic analysis using the brains of AD patients and 3xTg-AD mice showed altered abundance of O-GlcNAc peptides in AD (Alfaro et al., 2012; Forster et al., 2014; Wang et al., 2017) .
Therefore, disrupted O-GlcNAc modification is considered to be important for understanding the pathophysiology of AD. However, whether dysregulated O-GlcNAc cycling might be resulted from altered activity or substrate specificity of OGT and OGA in AD remains unclear. In addition, the role of O-GlcNAc modification in cell death associated with AD has not been studied so far. Although c-Fos is known to be an O-GlcNAcylated protein (Tai, Khidekel, Ficarro, Peters, & Hsieh-Wilson, 2004) , the specific dynamics and the effects of c-Fos O-GlcNAcylation require further investigation.
Here, we identified the O-GlcNAcylation sites on c-Fos and observed an increase in O-GlcNAcylation on c-Fos under conditions simulating AD, specifically in 5xFAD mouse which is well-known AD animal model and Aβ-treated neurons. In addition, we revealed that
Aβ-induced O-GlcNAcylation on c-Fos promotes neuronal cell death
by inducing the expression of apoptotic protein Bim, by elevating the transcriptional activity of c-Fos and increasing its stability. These novel findings contribute to understanding the link between glucose metabolism and neuronal cell death in the pathophysiology of AD.
| RESULTS

| Aβ increases c-Fos O-GlcNAcylation as well as the protein of c-Fos
Several reports show that the expression c-Fos is increased in the brains of patients with AD, and that c-Fos can be O-GlcNAcylated (Marcus et al., 1998; Tai et al., 2004) . Since O-GlcNAc cycling is altered in patients with AD (Forster et al., 2014; Liu et al., 2009; Zhu et al., 2014) , we hypothesized that c-Fos O-GlcNAcylation might be dysregulated in AD and play a role in its pathogenesis. To determine whether c-Fos O-GlcNAcylation is altered under conditions simulating AD, we pulled down O-GlcNAcylated proteins using wheat-germ-agglutinin (WGA)-conjugated agarose beads (that wellknown to bind to O-GlcNAc) in the brains of 5xFAD mice, a model of AD, and Aβ-treated primary cortical neurons and SH-SY5Y cells.
Although the levels of c-Fos were increased in 5xFAD as reported previously (Marcus et al., 1998) , we observed that c-Fos O-GlcNAcylation was also increased in 5xFAD compared to wild-type littermates, which was confirmed when the levels of pulled-down c-Fos (O-GlcNAcylated c-Fos) were normalized to the input level of c-Fos (Figure 1a-c) . We also found that both c-Fos and c-Fos O-GlcNAcylation levels were increased by Aβ in primary neurons and SH-SY5Y cells (Figure 1d-i) . In addition, when removing OGlcNAc using β-hexosaminidase (β-HEX), an O-GlcNAc-specific exoglycosidase that catalyzes the hydrolysis of β-D-N-acetylglucosamine residues, WGA-pulled-down c-Fos were remarkably decreased in the brains of 5xFAD mice and in the presence of Aβ, although the total levels of c-Fos levels were not changed (Supporting Information Figure S1 ). Especially, increased WGA-pulled-down c-Fos by Aβ were reduced even lower than vehicle group by β-HEX reaction, though, the input level of c-Fos was not changed (Supporting Information Figure S1b ). These data support that c-Fos O-GlcNAcylation was increased by Aβ.
Furthermore, to exclude the possibility of c-Fos induction by Aβ and confirm an increase in c-Fos O-GlcNAcylation, we performed immunoprecipitation of overexpressed exogenous c-Fos using an anti-GFP antibody (Figure 1j,k) . The increase in signals using CTD110.6 antibody, that specifically detects O-GlcNAc, clearly showed that c-Fos O-GlcNAcylation was increased by Aβ.
In addition, we proved that there were no nonspecific bindings during pull down assay and immunoprecipitation assay. To confirm nonspecific binding to beads, cell lysates were incubated with agarose beads, because we use WGA-coated-agarose beads when performing WGA-pull down assay, and there were no signals (2nd lane in Figure 3a and 1st lane in Supporting Information Figure S1b ).
Competitive assay using exogenously added GlcNAc to cell lysates, to confirm nonspecific binding to WGA, showed that O-GlcNAcylated c-Fos binds specifically to WGA (3rd and 4th lane in Figure 3a ).
In addition, no signal of WGA-pulled-down EGFP and no signal of 
| Aβ modulates the interaction between O-
GlcNAcase and c-Fos
Next, we wondered how Aβ dysregulates O-GlcNAc cycling. Forster et al. (2014) showed that the proteins of approximately 50 -60 kDa and 25 kDa in size show increased O-GlcNAcylation, while the proteins of over 70 kDa in size show reduced O-GlcNAcylation in the brains of patients with AD (Forster et al., 2014) . This suggested that O-GlcNAc cycling in AD was altered. Thus, increased O-GlcNAcylation on c-Fos, a 55 kDa protein, may be a result of altered O-GlcNAc cycling in AD. It has been reported that the interaction between OGT and its substrate (ATP synthase 5A) is altered by Aβ . Therefore, we wondered whether O-GlcNAc modifying enzymes (OGT or OGA) are involved in increased c-Fos O-GlcNAcylation by Aβ. Immunoprecipitation with GFP antibody, followed by Western blotting with c-Fos and OGT showed that the interaction between OGT and c-Fos was not changed by Aβ (Figure 2a,b) . However, the interaction between OGA and c-Fos was decreased by Aβ using immunoprecipitation with GFP and Western blotting with c-Fos and OGA (Figure 2c,d) . To confirm the less interaction between OGA and c-Fos by Aβ, imaging with structured illumination microscopy (SIM), which is a super-resolution microscopy, was performed.
It showed that less merged signals between c-Fos and OGA in the presence of Aβ (Figure 2e,f) . In addition, we also observed that the interaction between c-Fos and OGA was decreased in the brains of 5xFAD mice compared to wild-type littermate (Figure 2g,h ). This suggests that the ability of OGA to interact with c-Fos is altered by Aβ, resulting in increased O-GlcNAcylated c-Fos in the cells. Tai et al. (2004) residues. From these data, we carefully suggested that both S56 and S57 of c-Fos are the first identified O-GlcNAc sites on c-Fos.
| The mapping for O-GlcNAc sites of c-Fos
| O-GlcNAcylation of c-Fos promotes cell death in the presence of Aβ
Several studies show that c-Fos is involved in cell death under cytotoxic conditions because it regulates the transcription of apoptotic genes (Chen et al., 2015; Fernandez et al., 2005; Gillardon et al., 1996; Whitfield et al., 2001) . Aβ is a well-known cytotoxic protein that induces neurite atrophy, synaptic dysfunction, and neuronal cell death (Kumar et al., 2015; Querfurth & LaFerla, 2010) 
| O-GlcNAcylation of c-Fos increases its stability
Upon Aβ-induced increase in c-Fos O-GlcNAcylation, the total levels of c-Fos protein were also increased (Figure 1 ). Since N-terminal region of c-Fos is known to be a destabilizing region (Gomard et al., 
| Aβ-induced c-Fos O-GlcNAcylation regulates transcriptional activity of c-Fos and the expression of Bim
In the experiments illustrated in Figure 5 Recently, OGA inhibition has been evoked as one of the therapeutic strategies for AD Zhu et al., 2014) . This was supported by several studies showing that AD-like pathologies, such as memory impairment, hyperphosphorylated tau, neurofibrillary tangles, and Aβ plaques, were improved using OGA inhibitor for modulation of autophagy and the O-GlcNAcylation of tau, and Nicastrin, one of γ-secretase components (Kim et al., 2013; Graham et al., 2014; Yuzwa, Cheung, Okon, McIntosh, & Vocadlo, 2014; Yuzwa, Shan, et al., 2014; Zhu et al., 2018) . However, several researches suggested that down regulation of OGA caused proteotoxicity resulted from accumulation of aggregate-prone proteins such as huntingtin, Aβ and α-synuclein Wani et al., 2017) (Forster et al., 2014) . In addition, a recent study on proteomic analysis using the brains of AD patients showed increased abundance of O-GlcNAc peptides . Another proteomic study using 3xTg-AD mice reported that some of the O-GlcNAcylated proteins present only in 3xTg-AD mice (Alfaro et al., 2012) . These data suggested that O-GlcNAc cycling in AD was altered rather than simply reduced. Thus, The regulation of O-GlcNAc cycling seems to be complicated and the levels and activities of O-GlcNAc modifying enzymes seemed not to be changed in AD . Nevertheless, there are several possible regulatory mechanisms. First, the interactions between O-GlcNAc modifying enzymes (OGT or OGA) and their substrates might be altered. It has been reported that the interaction between OGT and its substrate (ATP synthase 5A) is altered by hindering inhibition of Aβ . We also observed that the interaction between OGA and c-Fos was reduced. Second, there were reports that several kinases regulate substrate specificities of OGT and OGA (Nagel & Ball, 2014) . For example, p38 MAPK affects O-GlcNAcylation of neurofilament H in neuroblastoma cells by interacting with OGT and not affecting phosphorylation (Cheung & Hart, 2008) . Although these phenomena have not been tested in AD condition, it is known that kinases are dysregulated in AD (Dolan & Johnson, 2010; Perluigi, Barone, Domenico, & Butterfield, 2016) .
Thus, kinases might be involved in altered O-GlcNAc cycling such as disrupted OGA and c-Fos interaction in AD. Third, phosphorylation might affect O-GlcNAcylation by competitive or synergistic manner (Bond & Hanover, 2015) . A recent study revealed that the phosphorylation/O-GlcNAcylation interplay motif, (pS/pT)P(V/A/T)(gS/gT), and around O-GlcNAcylation sites of tau resemble to this motif (Leney, Atmioui, Wu, Ovaa, & Heck, 2017) . However, S56 and S57 containing peptide of c-Fos is different from that motif, and there has been no report about phosphorylation around or on S56 and S57 of c-Fos so far. Thus, c-Fos O-GlcNAcylation may be regulated differently from tau. Although we described possible O-GlcNAc regulatory mechanisms, the precise regulatory mechanism of decreased OGA binding to c-Fos in response to Aβ and altered O-GlcNAc cycling in AD needs to be further studied. In addition, it requires further investigation whether O-GlcNAcylation on substrates affect the ability of interaction between O-GlcNAc modifying enzymes and substrates or not.
We revealed that c-Fos O-GlcNAcylation at S56 and S57 can improve its stability. It has been reported that N-terminal region of c-Fos is a destabilizer (Ferrara et al., 2003; Gomard et al., 2008) , altering the three-dimensional configuration of these components (Bannister & Kouzarides, 1995; Canettieri et al., 2009; Vierbuchen et al., 2017) . However, the precise underlying mechanisms need further investigation.
Several AP-1 target genes under cytotoxic stimuli have been described, such as Fas ligand (FasL), Fas, and Bim (Chen et al., 2015; Shaulian & Karin, 2002; Whitfield et al., 2001) . We tested the levels of these proteins in our experiments, and observed that those of Dysregulated glucose metabolism is involved in several human diseases such as diabetes mellitus and AD (Bond & Hanover, 2015) .
O-GlcNAc cycling, altered in the brains of patients with AD, reflects dysregulated glucose metabolism (Schubert, 2005; Zhu et al., 2014) .
Here NIH publication No. 85-23, revised 1985) and the Animal Care and Use Guidelines of Seoul National University, Seoul, Korea. All experimental protocols were approved by Institutional Animal Care and Use Committee (IACUC) at Seoul National University.
| Primary neuronal culture
Primary cortical neuronal cultures were prepared as previously described (Jung, An, Hong, Kim, & Mook-Jung, 2012 WT and c-Fos-S56A-S57A) were used. Tag-free c-Fos-WT plasmid was purchased from OriGene (USA). c-Fos-S56A-S57A plasmid was generated by introducing a point mutation into c-Fos-WT plasmid using a site-directed mutagenesis kit (Enzynomics, Korea) according to manufacturer's instructions. EGFP-tagged c-Fos constructs were generated using Gateway cloning technology (Invitrogen, USA).
AP-1-luc plasmid, containing luciferase gene under transcriptional control of AP-1 promoter, was purchased from Promega (USA).
OGT siRNA was predesigned and synthesized by Bioneer (Korea).
Thiamet G and β-hexosaminidase were purchased from Sigma (USA)
and Aβ 1-42 peptides (American peptide and Bachem, USA) were used.
| Preparation of Aβ
Aβ 1-42 peptide (American peptide, USA and Bachem, Switzerland) was prepared as previously described (Byun et al., 2015) . In brief, and anti-β-actin (A5441, Sigma), anti-α-tubulin (05-829, Millipore, Germany).
| Fluorescence imaging
For analyzing OGA and c-Fos interaction, we performed immunocytochemistry as previously described . 
| Calcein-AM assay
For measuring cell viability, cells were incubated with 1 μM of Calcein-AM (Invitrogen, USA) in DMEM for 1 hr at 37°C. After changing the medium to PBS, fluorescent signals were measured using luminometer (excitation at 490 nm and emission at 520 nm).
| MTS assay
For measuring cell viability, cells were treated with MTS solution (Promega, USA) in cell culture medium. After 1 hr incubation at 37°C, signals were measured using a spectrophotometer at 490 nm.
| Luciferase assay
The cells transfected with AP-1-luc plasmid were lysed in passive lysis buffer (Promega, USA). Equal amounts of cell lysates were mixed with a luciferase assay reagent (Promega, USA), and then the measurement was performed using luminometer. These processes were performed according to manufacturer's instructions (Promega, USA). 
| Statistical analysis
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